Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - Deferred ChargesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

HealthLynked (HLYK) EBITDA (2016 - 2025)

HealthLynked (HLYK) has disclosed EBITDA for 10 consecutive years, with -$709049.0 as the latest value for Q4 2025.

  • Quarterly EBITDA fell 126.56% to -$709049.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$3.0 million through Dec 2025, down 154.54% year-over-year, with the annual reading at -$587029.0 for FY2025, 49.93% up from the prior year.
  • EBITDA for Q4 2025 was -$709049.0 at HealthLynked, up from -$716499.0 in the prior quarter.
  • The five-year high for EBITDA was $2.7 million in Q4 2024, with the low at -$4.1 million in Q4 2022.
  • Average EBITDA over 5 years is -$940305.6, with a median of -$1.1 million recorded in 2023.
  • The sharpest move saw EBITDA crashed 414.21% in 2022, then soared 346.99% in 2024.
  • Over 5 years, EBITDA stood at $1.3 million in 2021, then plummeted by 414.21% to -$4.1 million in 2022, then surged by 73.77% to -$1.1 million in 2023, then soared by 346.99% to $2.7 million in 2024, then tumbled by 126.56% to -$709049.0 in 2025.
  • According to Business Quant data, EBITDA over the past three periods came in at -$709049.0, -$716499.0, and -$655542.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.